Apellis reports PhII ALS fail after stopping open-label extension in April
Apellis and Sobi will discontinue development in ALS after their approved rare blood and eye disease drug failed a Phase II study.
The pair was trying to see if pegcetacoplan, greenlighted in two different indications since 2021, could also help patients with the fatal neurodegenerative disease. But pegcetacoplan missed its primary endpoint of the “Combined Assessment of Function and Survival” rank score after a year, and also missed several secondary goals.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters